QUINCE THERAPEUTICS INC

QNCXNASDAQ

🏆 #3570 by market capEarnings Nov 10US Equity

$379.42▲ $29.29 (+7.72%)

Simulated price

1h—

24h▲ 7.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$31M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for QNCX.

Trading Snapshot

Day Range: $373.51 – $383.31
52-Week Range: $15.10 – $910.00
Volume: $3.39B
Avg Volume: $2.42B
Shares Outstanding: 980,000
Next Earnings: Sep 13, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $922,078
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-116.84
Dividend Yield: —

Why Investors Own QNCX

✓High-growth profile — revenue up +53.8% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$4M▲ +57.6% YoY

Gross Margin (TTM)

62.6%▲ +2.6% YoY

Operating Income (TTM)

$1M▲ +57.6% YoY

Free Cash Flow (TTM)

$474,679▲ +57.6% YoY

About QUINCE THERAPEUTICS INC

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

🦦